Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan

Taiji Sogou, Keiichi Mashima, Nobuhiko Ohnishi, Ryouko Shinohata, Chisato Suezawa, Masayuki Ueeda, Youkou Tominaga, Hiromachi Ohnishi, Shozo Kusachi, Takaaki Nakatsu, Atsushi Takaishi, Akihiro Iwabu, Tadaichi Uesugi

Research output: Contribution to journalArticle

Abstract

Objectives: We examined the clinical characteristics of the efficacy of pitavastatin in connection with gender, age and low density lipoprotein (LDL) size. Patients and Methods: A total of 112 patients were analyzed: 61 de navo patients with hyperlipidemia and 51 patients with insufficient treatment of hyperlipidemia with another statin. Pitavastatin was administered at 1-4 mg a day depending on serum lipid levels. Results: In the 61 de novo patients, pitavastatin decreased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) by 29.7 and 42.3%, respectively, without any adverse effects (TC, from 250.5 ± 37.0 to 174.8 ± 26.6 mg/dL; LDL-C, from 155.4 ± 39.8 to 87.4 ± 23.3 mg/dL). The lipid-lowering effects were not different between men and women and were observed throughout all age groups. In patients with insufficient treatment of hyperlipidemia with another statin, replacement with pitavastatin significantly decreased serum lipid levels (TC, from 230.3 ± 35.5 to 183.6 ± 21.6 mg/dL; LDL-C, from 138.4 ± 36.8 to 99.4 ± 27.2 mg/dL). Pitavastatin significantly increased LDL particle size by approximately 1% in both de novo patients and patients with pitavastatin replacement. Conclusions: The present study revealed that pitavastatin has potent lipid-lowering effects without gender and age-group differences, and significantly increased LDL particle size.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalTherapeutic Research
Volume30
Issue number2
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Japan
Lipids
LDL Lipoproteins
Hyperlipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
Particle Size
Age Groups
Surveys and Questionnaires
pitavastatin
Serum
LDL Cholesterol
Therapeutics

Keywords

  • Hyperlipidemia
  • Low density lipoprotein size
  • Pitavastatin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sogou, T., Mashima, K., Ohnishi, N., Shinohata, R., Suezawa, C., Ueeda, M., ... Uesugi, T. (2009). Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan. Therapeutic Research, 30(2), 189-198.

Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan. / Sogou, Taiji; Mashima, Keiichi; Ohnishi, Nobuhiko; Shinohata, Ryouko; Suezawa, Chisato; Ueeda, Masayuki; Tominaga, Youkou; Ohnishi, Hiromachi; Kusachi, Shozo; Nakatsu, Takaaki; Takaishi, Atsushi; Iwabu, Akihiro; Uesugi, Tadaichi.

In: Therapeutic Research, Vol. 30, No. 2, 2009, p. 189-198.

Research output: Contribution to journalArticle

Sogou, T, Mashima, K, Ohnishi, N, Shinohata, R, Suezawa, C, Ueeda, M, Tominaga, Y, Ohnishi, H, Kusachi, S, Nakatsu, T, Takaishi, A, Iwabu, A & Uesugi, T 2009, 'Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan', Therapeutic Research, vol. 30, no. 2, pp. 189-198.
Sogou, Taiji ; Mashima, Keiichi ; Ohnishi, Nobuhiko ; Shinohata, Ryouko ; Suezawa, Chisato ; Ueeda, Masayuki ; Tominaga, Youkou ; Ohnishi, Hiromachi ; Kusachi, Shozo ; Nakatsu, Takaaki ; Takaishi, Atsushi ; Iwabu, Akihiro ; Uesugi, Tadaichi. / Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan. In: Therapeutic Research. 2009 ; Vol. 30, No. 2. pp. 189-198.
@article{835cc3ef38d44861a8cfd4a5ed7fd759,
title = "Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan",
abstract = "Objectives: We examined the clinical characteristics of the efficacy of pitavastatin in connection with gender, age and low density lipoprotein (LDL) size. Patients and Methods: A total of 112 patients were analyzed: 61 de navo patients with hyperlipidemia and 51 patients with insufficient treatment of hyperlipidemia with another statin. Pitavastatin was administered at 1-4 mg a day depending on serum lipid levels. Results: In the 61 de novo patients, pitavastatin decreased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) by 29.7 and 42.3{\%}, respectively, without any adverse effects (TC, from 250.5 ± 37.0 to 174.8 ± 26.6 mg/dL; LDL-C, from 155.4 ± 39.8 to 87.4 ± 23.3 mg/dL). The lipid-lowering effects were not different between men and women and were observed throughout all age groups. In patients with insufficient treatment of hyperlipidemia with another statin, replacement with pitavastatin significantly decreased serum lipid levels (TC, from 230.3 ± 35.5 to 183.6 ± 21.6 mg/dL; LDL-C, from 138.4 ± 36.8 to 99.4 ± 27.2 mg/dL). Pitavastatin significantly increased LDL particle size by approximately 1{\%} in both de novo patients and patients with pitavastatin replacement. Conclusions: The present study revealed that pitavastatin has potent lipid-lowering effects without gender and age-group differences, and significantly increased LDL particle size.",
keywords = "Hyperlipidemia, Low density lipoprotein size, Pitavastatin",
author = "Taiji Sogou and Keiichi Mashima and Nobuhiko Ohnishi and Ryouko Shinohata and Chisato Suezawa and Masayuki Ueeda and Youkou Tominaga and Hiromachi Ohnishi and Shozo Kusachi and Takaaki Nakatsu and Atsushi Takaishi and Akihiro Iwabu and Tadaichi Uesugi",
year = "2009",
language = "English",
volume = "30",
pages = "189--198",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "2",

}

TY - JOUR

T1 - Characteristics of lipid-lowering effects of pitavastatin according to a survey in Japan

AU - Sogou, Taiji

AU - Mashima, Keiichi

AU - Ohnishi, Nobuhiko

AU - Shinohata, Ryouko

AU - Suezawa, Chisato

AU - Ueeda, Masayuki

AU - Tominaga, Youkou

AU - Ohnishi, Hiromachi

AU - Kusachi, Shozo

AU - Nakatsu, Takaaki

AU - Takaishi, Atsushi

AU - Iwabu, Akihiro

AU - Uesugi, Tadaichi

PY - 2009

Y1 - 2009

N2 - Objectives: We examined the clinical characteristics of the efficacy of pitavastatin in connection with gender, age and low density lipoprotein (LDL) size. Patients and Methods: A total of 112 patients were analyzed: 61 de navo patients with hyperlipidemia and 51 patients with insufficient treatment of hyperlipidemia with another statin. Pitavastatin was administered at 1-4 mg a day depending on serum lipid levels. Results: In the 61 de novo patients, pitavastatin decreased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) by 29.7 and 42.3%, respectively, without any adverse effects (TC, from 250.5 ± 37.0 to 174.8 ± 26.6 mg/dL; LDL-C, from 155.4 ± 39.8 to 87.4 ± 23.3 mg/dL). The lipid-lowering effects were not different between men and women and were observed throughout all age groups. In patients with insufficient treatment of hyperlipidemia with another statin, replacement with pitavastatin significantly decreased serum lipid levels (TC, from 230.3 ± 35.5 to 183.6 ± 21.6 mg/dL; LDL-C, from 138.4 ± 36.8 to 99.4 ± 27.2 mg/dL). Pitavastatin significantly increased LDL particle size by approximately 1% in both de novo patients and patients with pitavastatin replacement. Conclusions: The present study revealed that pitavastatin has potent lipid-lowering effects without gender and age-group differences, and significantly increased LDL particle size.

AB - Objectives: We examined the clinical characteristics of the efficacy of pitavastatin in connection with gender, age and low density lipoprotein (LDL) size. Patients and Methods: A total of 112 patients were analyzed: 61 de navo patients with hyperlipidemia and 51 patients with insufficient treatment of hyperlipidemia with another statin. Pitavastatin was administered at 1-4 mg a day depending on serum lipid levels. Results: In the 61 de novo patients, pitavastatin decreased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) by 29.7 and 42.3%, respectively, without any adverse effects (TC, from 250.5 ± 37.0 to 174.8 ± 26.6 mg/dL; LDL-C, from 155.4 ± 39.8 to 87.4 ± 23.3 mg/dL). The lipid-lowering effects were not different between men and women and were observed throughout all age groups. In patients with insufficient treatment of hyperlipidemia with another statin, replacement with pitavastatin significantly decreased serum lipid levels (TC, from 230.3 ± 35.5 to 183.6 ± 21.6 mg/dL; LDL-C, from 138.4 ± 36.8 to 99.4 ± 27.2 mg/dL). Pitavastatin significantly increased LDL particle size by approximately 1% in both de novo patients and patients with pitavastatin replacement. Conclusions: The present study revealed that pitavastatin has potent lipid-lowering effects without gender and age-group differences, and significantly increased LDL particle size.

KW - Hyperlipidemia

KW - Low density lipoprotein size

KW - Pitavastatin

UR - http://www.scopus.com/inward/record.url?scp=63049112415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049112415&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:63049112415

VL - 30

SP - 189

EP - 198

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 2

ER -